Daily administration of liraglutide 3 mg for 32 weeks in obese women with polycystic ovary syndrome causes a mean weight reduction of 5.7% compared to a 1.4% reduction with placebo, and significantly improves body composition and metabolic health by reducing fat mass and visceral adipose tissue.

Liraglutide signals the brain to reduce hunger and slow digestion, causing less food intake and fat loss, especially around the belly. As belly fat shrinks, inflammation drops, which allows the body to respond better to insulin. Lower insulin levels reduce male hormone production in the ovaries, helping follicles mature normally and restoring regular periods. The liver also burns more fat and stores less, reducing fat buildup and liver damage.